Direct Ras G12C inhibitors: crossing the rubicon

Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered ‘undruggable’. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindsay, Colin R., Blackhall, Fiona H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738074/
https://www.ncbi.nlm.nih.gov/pubmed/31239544
http://dx.doi.org/10.1038/s41416-019-0499-1
_version_ 1783450777928335360
author Lindsay, Colin R.
Blackhall, Fiona H.
author_facet Lindsay, Colin R.
Blackhall, Fiona H.
author_sort Lindsay, Colin R.
collection PubMed
description Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered ‘undruggable’. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures.
format Online
Article
Text
id pubmed-6738074
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67380742019-09-12 Direct Ras G12C inhibitors: crossing the rubicon Lindsay, Colin R. Blackhall, Fiona H. Br J Cancer Editorial Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered ‘undruggable’. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures. Nature Publishing Group UK 2019-06-26 2019-07-30 /pmc/articles/PMC6738074/ /pubmed/31239544 http://dx.doi.org/10.1038/s41416-019-0499-1 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Editorial
Lindsay, Colin R.
Blackhall, Fiona H.
Direct Ras G12C inhibitors: crossing the rubicon
title Direct Ras G12C inhibitors: crossing the rubicon
title_full Direct Ras G12C inhibitors: crossing the rubicon
title_fullStr Direct Ras G12C inhibitors: crossing the rubicon
title_full_unstemmed Direct Ras G12C inhibitors: crossing the rubicon
title_short Direct Ras G12C inhibitors: crossing the rubicon
title_sort direct ras g12c inhibitors: crossing the rubicon
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738074/
https://www.ncbi.nlm.nih.gov/pubmed/31239544
http://dx.doi.org/10.1038/s41416-019-0499-1
work_keys_str_mv AT lindsaycolinr directrasg12cinhibitorscrossingtherubicon
AT blackhallfionah directrasg12cinhibitorscrossingtherubicon

Ejemplares similares